Skip to main content

Table 1 Patient information, tumor characteristics, Miller-Payne Grade, initial tumor size (MRI/PET and US), and treatment regimen

From: Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters

Age

Tumor type

NS

Mitotic count/10 HPF

TN

HER2/ER

Miller-Payne grade

Tumor size (MRI/PET)

Tumor size (US)

Treatment

regimen

59

IDC

6

2

–

−/+

3

2.7

1.7

ACT

55

ILC

6

1

–

−/+

4

8.6

–a

ACT

33

IDC

4

2

–

−/+

3

1.6

1.5

ACT

61

IDC/ILC

6

1

+

−/−

1

3.3

1.9

ACT

59

IDC

6

5

–

−/+

2

5.6

2.2

ACT

68

IDC

6

3

–

−/+

3

7.6

2.2

ACT

51

IDC

9

40

+

−/−

5

3.6

2.2

ACT

53

IDC

9

62

+

−/−

3

PET: 3.7

4.3

ACT

         

TPT

51

IDC

7

15

–

+/+

5

N/A

1.2

TPT

74

IDC

8

8

–

+/−

5

6.2

–a

TPT

57

IDC

9

16

–

+/−

4

6.9

–b

TPT&FEC

         

TPT

51

IDC

9

14

–

+/−

5

3.0

1.9

TPT

59

IDC

7

1

–

+/+

5

N/A

0.6

TPT

61

IDC

4

3

–

+/+c

5

2.0

1.4

TPT

37

IDC/ILC

8

9

–

+/+

4

3.6

1.9

TPT

54

IDC

8

20

–

+/+

5

2.9

2.3

TPT

40

IDC

8

15

–

+/+

5

2.2

2.1

TPT

62

IDC

9

12

–

+/+

3

PET: 1.8

1.2

TPT

37

IDC

8

42

–

+/+c

5

1.5

1.6

TPT

72

IDC

9

42

–

−/+

3

4.3

2.3

TC

57

IDC

9

14

+

−/−

5

2.3

1.3

Carbo/T

41

IDC

9

8

+

−/−

3

4.0

4.0

Carbo/T

  1. aNot US visible
  2. bMuch larger than the size of the US transducer
  3. cER showed a weak positive result
  4. ACT, dose-dense doxorubicin/cyclophosphamide and paclitaxel; Carbo/T, carboplatin and paclitaxel, ER estrogen receptor, FEC 5flurouracil, epirubicin, and cyclophosphamide, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, MRI magnetic resonance imaging, N/A not available, NS Nottingham Score (out of 9), PET positron emission tomography, TC cyclophosphamide and docetaxel, TN triple negative, TPT TP and taxane-based therapy—trastuzumab, pertuzumab and docetaxel or paclitaxel with or without carboplatin, TPT&FEC trastuzumab, pertuzumab, paclitaxel; 5flurouracil, epirubicin, cyclophosphamide, US ultrasound